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Abstract Background The use of receiver operating characteristic curves, or “ROC analysis,”
has become quite common in biomedical research to support decisions. However,
sensitivity, specificity, and misclassification rates are still often estimated using the
training sample, overlooking the risk of overrating the test performance.
Methods A simulation study was performed to highlight the inferential implications
of splitting (or not) the dataset into training and test set. The normality assumption was
made for the classifier given the disease status, and the Youden’s criterion considered
for the detection of the optimal cutoff. Then, an ROC analysis with sample split was
applied to assess the discriminant validity of the Italian version of the Control of Allergic
Rhinitis and Asthma Test (CARATkids) questionnaire for children with asthma and
rhinitis, for which recent studies may have reported liberal performance estimates.
Results The simulation study showed that both single split and cross-validation (CV)
provided unbiased estimators of sensitivity, specificity, and misclassification rate,
therefore allowing computation of confidence intervals. For the Italian CARATkids
questionnaire, the misclassification rate estimated by fivefold CV was 0.22, with 95%
confidence interval 0.14 to 0.30, indicating an acceptable discriminant validity.
Conclusions Splitting into training and test set avoids overrating the test perfor-
mance in ROC analysis. Validated through thismethod, the Italian CARATkids is valid for
assessing disease control in children with asthma and rhinitis.
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Introduction
The use of receiver operating characteristic curves, or “ROC
analysis,” has become quite common in biomedical research
to support decisions.1–3 In fact, continuous developments in
clinical, biological, and psychometric methods provide a
wide range of measurements that can be evaluated as
potential diagnostic or prognostic tools. Several advanced
nonparametric, semiparametric, and parametric methods
have been developed for estimating and comparing ROC
curves derived from continuous classifiers.4 However, the
most widespread approach to ROC analysis, routinely used
in a clinical setting, is still the simplest one: several values
of some numerical (continuous or discrete) classifier are
evaluated as possible “optimal” cutoff for labeling individu-
als as “diseased” or “nondiseased.”5–8 The goal is to set up a
simple screening test, therefore avoiding performing a more
invasive, expensive, or time-consuming “gold standard”
test.
To derive a ROC curve, sensitivity is plotted against one
minus specificity derived from cross-tabulations (CVs) of the
true binary status and several binary classifiers obtained
through different cutoffs. Different criteria have been pro-
posed for establishing the “optimal” cutoff,mainly based on a
trade-off between sensitivity and specificity. However, there
is no general criterion that guarantees optimality in all
situations, since optimality may depend on different test
characteristics and implications (costs, psychological con-
sequences) of false positivities and false negativities. The
most widely used criteria are minimization of the distance
from (0,1)9 and maximization of the Youden’s index (sensi-
tivityþ specificity-1),10 the latter being somewhat more
appropriate.11 Sensitivity, specificity, and misclassification
rates, obtained with the optimal cutoff, together with the
area under the ROC curve, are commonly used to report the
predictive performance of a classifier.12,13
The need to assess the predictive performance of a
classifier on an independent test sample has been well
demonstrated, for example, in the context of machine learn-
ing,14 decision trees,15 and penalized least square discrimi-
nant analysis.16 By contrast, this topic appears to have been
overlooked inmedical literature about ROC analysis, with the
result that the aforementioned performance indicators are
still quite often estimated using the same sample of data
where the test was developed.
Although the issue of deriving appropriate estimators for
the performance error rates could be bypassed using
parametric17–19 or Bayesian approaches,15 these methods
may be unfamiliar to medical researchers. In addition, the
main issue of the training-test set approach is the choice of
the training set proportion (usually 1:2 or 2:3), especially
when the sample size is small.20 An alternative approach is
CV.21,22 CV leaves out one or more observations in turn to
be used as the test sample; all the test samples form a
partition of the whole sample, so that all the observations
are involved in estimation of the classification error. The
dilemma, however, is about choosing the classifier to retain,
since different classifiers may be obtained from different
training subsets. In general, one may then return to the full
dataset.23
The motivation for writing this article concerns the
increasing acknowledgment of the prognostic value of pa-
tient-reported outcomes in patients with asthma,24 rhini-
tis,25,26 or both.27,28 In fact, recent studies have provided
simple screening tests for assessing the disease control and
therefore monitoring its course. However, out of the five
studies referenced above, only one24 appears to have ran-
domly divided the total sample into a “development” (or
“training”) sample (75%) and a “confirmatory” (or “ test”)
sample (25%). In particular, for pediatric patients with
asthma and rhinitis, one of the previous validation studies
of the “Control of Allergic Rhinitis and Asthma Test” (Control
of Allergic Rhinitis and Asthma Test (CARAT) CARATkids
questionnaire) in Brazilian children27 reported an estimated
probability of 1 for the CARATkids score being larger than 3
with uncontrolled asthma (sensitivity), and an estimated
probability of 0.93 for the CARATkids score being lower than
7 with controlled asthma (specificity). Since they report
sensitivity and specificity from the same sample where
they were maximized, such estimates may be affected by
positive bias, that is, they probably overestimate the true
sensitivity and specificity in the general population.
The aim of this study was to highlight the positive
inferential implications of splitting the study sample into a
training sample (where the optimal test is derived) and a test
sample (where performance or error rates are estimated) in
the setting of ROC analysis. This was accomplished by using a
well-known data generating mechanisms and a simple sim-
ulation study, as a possible reference for medical researchers
dealing with such data.
Methods
Statistical Characterization
Let Yi be a dichotomous random variable for which
i¼1,2,…,n, where n is the size of a given sample of individu-
als from some target population. It is possible to define
as the prevalence of the disease in the target population. Now
consider a quantitative randomvariable Xi, and suppose that,
on average, the X values are greater in diseased individuals.
Given this property, Xi may be considered as a potential
classifier for Yi. For the illustrative purpose of this article, the
distribution of Xi conditional to the disease status is sup-
posed to be Normal (or Gaussian), so that
σ
σ
μ
μ
Here μ1 and σ1 are, respectively, the true mean and standard
deviation of the classifier among nondiseased individuals,
while μ2 and σ2 are their counterparts among diseased
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individuals (with μ2>μ1). On this ground, the rationale of
ROC analyses is that the “working variable”
can be used as a simple classification rule in the target
population for some given cutoff c. The accuracy of the
test depends on its ability to correctly detect diseased and
nondiseased individuals. In particular, the performance
indicators of interest are usually sensitivity (probability
that the test is positive in diseased individuals), specificity
(probability that the test is negative in nondiseased indi-
viduals), and the misclassification rate (probability of
incorrectly classifying an individual). The true perfor-
mance has to be evaluated in the target population, and
of course, it depends on the cutoff c. The true sensitivity is
defined as:
μ σ
where Φ(·) represents the Gaussian distribution function,
with parameters of the diseased population in this case.
Similarly, the true specificity is:
μ σ
where now the distribution ofX in nondiseased individuals is
involved. Finally, the true misclassification rate is:
In ROC analyses, pairs (xi,yi) are collected on n individuals; in
particular, the disease status yi is assessed through some
validated gold standard test. To set up the classification rule,
the cutoff to use is selected among several candidates on a
grid of x values, as the value that optimizes a given criterion.
The sample of individuals on which this optimization is
performed is called the “training set.” The size of the training
set will be denoted by nδ, where δ¼nδ/n (e.g., δ¼50%,
δ¼67% or δ¼100%) indicates the training percentage.
According to Youden’s criterion,10 the optimal cutoff is
estimated as:
δ
δ δ
δ
δ δ
δ∑ ∑
∑∑
where cj is the j-th candidate cutoff on a J-dimensional
discrete grid of x values, δ is the test sensitivity in the
training sample, and δ is the test specificity in the training
sample.
Once the optimal cutoff ĉδ has been identified using the
training set, the next step is to estimate the true predictive
performance of the optimized test, that is, to estimate (2),
(3), and (4) for c¼ ĉδ. To accomplish this, two simple
approaches are commonly used. The first, liberal approach
consists in estimating the performance in the training set:
δ
δ
δ∑
∑δ
δ
δ
δ
δδ
∑
∑
δ δ δ δ δ δ δ δ
If the true disease prevalence (i.e., the prevalence in the
general population) is simply estimated by δ
δ
δ∑
(i.e., the
prevalence in the study sample), Eq. (8) reduces to the
following, more familiar expression:
δ δ
δ
δ
δ∑
where I(·) is an indicator function. However, if the number of
diseased and nondiseased individuals is fixed a priori in the
study design, using Eq. (9) would be definitely wrong for
obvious reasons; in this case, the true prevalence should be
inferred from previous studies or just hypothesized.
Thesecond,moreconservativeapproachconsistsinrandomly
leaving out a given proportion of the sample, say γ individuals
(e.g., γ or γ ), to use as the test sample, that is, to
estimate (2), (3), and (4) for c¼ ĉδ, where ĉδ comes from the
training sample ( γδ ). The performance estimators
will therefore be denoted with γ δ , γ δ , and γ δ .
Sometimes, separation into a training and a test set is
difficult due to the small sample size. In this case, k-fold CV
makes better use of the data. With this approach, the whole
sample is randomly partitioned into k subgroups to be used
as the test set in different steps. At each step, k1 groups
(training set) are used to develop a classifier, and the
outcome predictions are derived in the test set. This proce-
dure is repeated until all the k subgroups have been used as
the test set, and the overall classifier performance is there-
fore evaluated. The main issue with this approach is the
choice of the classifier to retain, since different classifiers
may be obtained at each step; in this case, one may return to
the full dataset using ĉ100%.23 The k-fold CV performance
estimators will be denoted with , and ; when k¼n, CV
is referred to as leave-one-out CV (LOOCV).
The next section is intended to show, empirically, that the
first approach (100% training) leads to an overestimation of
the true sensitivity and specificity (and consequently an
underestimation of the misclassification rate in the target
population), while the second approach (independent test
sample) provides unbiased estimates. The following true
performance indicators, averaged over ĉδ, will be considered
for the different procedures (δ¼100%, δ¼67% and δ¼50%):
δδ Σ
δ δ∑
δδ ∑
where the termsprob(ĉδ¼ cj) are estimated through simulation.
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Simulation Study
In the simulation study showed in the next section, the n
pairs (yi,xi) were generated as follows: first, yi was generated
from a Bernoulli random variable with probability of success
equal to p, then, xi was generated from a Gaussian distribu-
tion, using parameters μ1 and σ if yi¼0, μ2 and σ if yi¼1.
Simulations were performed to assess the true sensitivity,
the specificity and the misclassification rate, and the prop-
erties of the estimators presented in the previous section.
Different configurations of target populations were con-
sidered by varying the mean difference (distances between
μ1 and μ2, δμ¼2, 4, 6, 8), the variances [(σ1, σ2)¼ (1, 4), (2, 3),
(2, 2), (3, 2), (4, 1)] and the disease prevalence (p¼0.6, 0.4).
►Figure 1 illustrates the hypothesized populations of dis-
eased and nondiseased individuals. From each population,
1,000 random data samples were generated using different
sample sizes (n¼50, 100, 200). For each simulated sample, a
ROC analysis was performed to detect the optimal cutoff
using Youden’s criterion (on a discrete grid of J¼30 equally
spaced candidates cj), and the performance of the obtained
test was estimated using different training percentages
(δ¼100%, 67%, 50%), fivefold CV and LOOCV.
Clinical Data
The data analyzed in the article come from a cross-sectional
study performed at the Pediatric Pulmonology-Allergology
outpatient clinic of the CNR Institute for Biomedical Research
and Innovation of Palermo, and at the Department of Pediat-
rics of the Sapienza University of Rome, Italy. Children aged 6
to 11 years, with a medical diagnosis of allergic rhinitis and
asthma, were consecutively enrolled from March 2015 to
December 2016. Children with other respiratory or chronic
diseases that might interfere with the study measurements,
as well as children with psychiatric disorders and/or cogni-
tive impairment, were excluded. The n¼112 patients were
assessed at baseline (T0) and after amean period of 3months
(T1). All children attended both visits and completed an
Italian version of the CARATkids questionnaire27–29 and
the Childhood Asthma Control Test (C-ACT).24
Some psychometric characteristics of the Italian CARAT-
kids questionnaire were assessed. In particular, the discrimi-
nant validity of CARATkids was evaluated in previous
studies27,28 as its ability to detect childrenwith uncontrolled
asthma, defined as C-ACT score 19.24 Moreover, the more
general cross-sectional and longitudinal validitywas assessed
through the correlation between the total score of the
CARATkids and the total score of C-ACT. A ROC analysis
was performed and the optimal cutoff value for CARATkids
selected according to Youden’s method. The area under the
curve (AUC) was estimated and its significance (AUC>0.5)
tested using the method described by DeLong et al.30
The study was approved by the local ethic committee (N
11/2014 Azienda ospedaliera Universitaria Policlinico Paolo
Giaccone) and conducted in accordancewith the Declaration
of Helsinki and Good Clinical Practice guidelines. All parents
provided written informed consent. The study was regis-
tered on the central registration system ClinicalTrials.gov
(NCT 02409550).
Results
Simulation Study
►Tables 1 to 6 show the means and standard deviations
of the different estimates obtained in the simulated data
samples. Scenarios with δμ¼2, 8 were reported in
►Supplementary Tables S1 to S6 (online only). In general,
small differences are observed in the expected value of the
cutoff estimator (ĉ), which locates approximately at the
intersection point between the distributions in ►Fig. 1,
that is, the optimal cutoff in the population. As expected,
Fig. 1 Theoretical scenarios of populations considered in the simulation study. Gray curves indicate nondiseased individuals, and black curves
indicate diseased individuals.
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Table 1 Simulated means and standard deviations (σ) of the detected cutoff (ĉ), and of estimated sensitivity , specificity , and
misclassification rate ( ) with n¼ 50 and p¼0.60. Se, Sp, and indicate the true performances
Δμ σ1, σ2 δ ĉ σĉ Se Sp
4 1, 4 100% 1.660 0.512 0.719 0.738 0.085 0.930 0.974 0.043 0.196 0.168 0.052
67% 1.560 0.539 0.727 0.729 0.151 0.916 0.921 0.131 0.197 0.195 0.098
50% 1.473 0.576 0.734 0.739 0.123 0.899 0.900 0.133 0.200 0.197 0.080
Fivefold CV 1.660 0.512 0.719 0.727 0.084 0.930 0.926 0.058 0.196 0.193 0.060
LOOCV 1.660 0.512 0.719 0.722 0.087 0.930 0.935 0.056 0.196 0.193 0.062
2, 3 100% 2.019 0.894 0.737 0.768 0.106 0.822 0.883 0.095 0.229 0.187 0.056
67% 2.021 0.986 0.734 0.731 0.169 0.818 0.824 0.192 0.232 0.233 0.106
50% 1.880 1.080 0.747 0.748 0.151 0.796 0.804 0.181 0.233 0.231 0.089
Fivefold CV 2.019 0.894 0.737 0.739 0.099 0.822 0.815 0.100 0.229 0.230 0.070
LOOCV 2.019 0.894 0.737 0.735 0.110 0.822 0.824 0.105 0.229 0.229 0.078
2, 2 100% 1.906 0.700 0.838 0.866 0.086 0.816 0.874 0.089 0.171 0.131 0.048
67% 1.881 0.813 0.837 0.836 0.153 0.808 0.813 0.190 0.175 0.174 0.098
50% 1.823 0.899 0.840 0.838 0.138 0.797 0.797 0.175 0.177 0.178 0.084
Fivefold CV 1.906 0.700 0.838 0.838 0.082 0.816 0.814 0.092 0.171 0.171 0.063
LOOCV 1.906 0.700 0.838 0.836 0.093 0.816 0.819 0.096 0.171 0.170 0.072
3, 2 100% 1.729 0.903 0.850 0.877 0.094 0.710 0.771 0.113 0.206 0.166 0.053
67% 1.668 1.067 0.848 0.848 0.156 0.700 0.701 0.213 0.211 0.211 0.104
50% 1.614 1.151 0.850 0.849 0.145 0.693 0.698 0.195 0.213 0.212 0.086
Fivefold CV 1.729 0.903 0.850 0.845 0.092 0.710 0.707 0.114 0.206 0.210 0.070
LOOCV 1.729 0.903 0.850 0.843 0.105 0.710 0.712 0.119 0.206 0.209 0.078
4, 1 100% 2.153 0.657 0.942 0.963 0.046 0.703 0.749 0.102 0.154 0.124 0.045
67% 2.023 0.866 0.942 0.940 0.100 0.690 0.695 0.204 0.159 0.157 0.090
50% 1.916 1.063 0.936 0.938 0.103 0.679 0.677 0.186 0.166 0.168 0.083
Fivefold CV 2.153 0.657 0.942 0.945 0.053 0.703 0.696 0.107 0.154 0.155 0.056
LOOCV 2.153 0.657 0.942 0.946 0.057 0.703 0.703 0.105 0.154 0.151 0.058
6 1, 4 100% 1.835 0.506 0.849 0.860 0.067 0.950 0.984 0.031 0.111 0.091 0.040
67% 1.721 0.584 0.855 0.853 0.120 0.932 0.931 0.121 0.114 0.117 0.081
50% 1.632 0.618 0.860 0.863 0.096 0.918 0.920 0.119 0.117 0.114 0.068
Fivefold CV 1.835 0.506 0.849 0.853 0.068 0.950 0.938 0.051 0.111 0.113 0.049
LOOCV 1.835 0.506 0.849 0.849 0.069 0.950 0.944 0.046 0.111 0.112 0.050
2, 3 100% 2.614 0.828 0.862 0.882 0.071 0.886 0.935 0.065 0.128 0.097 0.041
67% 2.567 0.937 0.863 0.859 0.125 0.878 0.883 0.150 0.131 0.132 0.081
50% 2.465 1.030 0.867 0.862 0.115 0.863 0.859 0.150 0.134 0.139 0.072
Fivefold CV 2.614 0.828 0.862 0.862 0.071 0.886 0.879 0.073 0.128 0.131 0.055
LOOCV 2.614 0.828 0.862 0.857 0.077 0.886 0.888 0.072 0.128 0.130 0.058
2, 2 100% 2.877 0.696 0.930 0.947 0.049 0.913 0.955 0.049 0.077 0.051 0.032
67% 2.734 0.802 0.935 0.935 0.093 0.898 0.895 0.142 0.080 0.082 0.070
50% 2.605 0.947 0.938 0.937 0.087 0.880 0.879 0.135 0.085 0.086 0.063
Fivefold CV 2.877 0.696 0.930 0.932 0.055 0.913 0.903 0.061 0.077 0.079 0.045
LOOCV 2.877 0.696 0.930 0.930 0.057 0.913 0.911 0.057 0.077 0.077 0.047
3, 2 100% 3.095 0.825 0.910 0.931 0.063 0.840 0.886 0.076 0.118 0.087 0.040
67% 3.005 0.999 0.910 0.906 0.120 0.829 0.823 0.170 0.122 0.127 0.086
50% 2.892 1.134 0.912 0.912 0.108 0.816 0.807 0.162 0.126 0.129 0.069
Fivefold CV 3.095 0.825 0.910 0.909 0.065 0.840 0.828 0.083 0.118 0.123 0.054
LOOCV 3.095 0.825 0.910 0.907 0.071 0.840 0.833 0.084 0.118 0.122 0.060
4, 1 100% 3.818 0.731 0.965 0.978 0.036 0.826 0.867 0.080 0.091 0.068 0.037
67% 3.679 0.929 0.964 0.963 0.079 0.815 0.812 0.171 0.096 0.097 0.075
50% 3.426 1.216 0.963 0.964 0.076 0.794 0.796 0.160 0.104 0.104 0.071
Fivefold CV 3.818 0.731 0.965 0.963 0.046 0.826 0.817 0.087 0.091 0.096 0.049
LOOCV 3.818 0.731 0.965 0.964 0.046 0.826 0.823 0.087 0.091 0.092 0.049
Abbreviation: LOOCV, leave-one-out cross-validation.
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Table 2 Simulated means and standard deviations (σ) of the detected cutoff (ĉ), and of estimated sensitivity , specificity , and
misclassification rate ( ) with n¼ 50 and p¼0.4. Se, Sp, and indicate the true performances
Δμ σ1, σ2 δ ĉ σĉ Se Sp
4 1, 4 100% 1.699 0.492 0.716 0.743 0.103 0.937 0.963 0.049 0.152 0.125 0.046
67% 1.635 0.532 0.721 0.715 0.192 0.926 0.926 0.107 0.156 0.157 0.091
50% 1.544 0.597 0.728 0.729 0.152 0.908 0.908 0.114 0.164 0.164 0.082
Fivefold CV 1.699 0.492 0.716 0.719 0.104 0.937 0.927 0.055 0.152 0.156 0.058
LOOCV 1.699 0.492 0.716 0.715 0.107 0.937 0.935 0.055 0.152 0.152 0.059
2, 3 100% 2.129 0.836 0.726 0.776 0.114 0.837 0.873 0.093 0.207 0.166 0.051
67% 2.087 0.965 0.728 0.730 0.203 0.826 0.827 0.162 0.213 0.211 0.103
50% 1.986 1.022 0.737 0.738 0.175 0.812 0.811 0.162 0.218 0.219 0.094
Fivefold CV 2.129 0.836 0.726 0.730 0.111 0.837 0.826 0.091 0.207 0.212 0.069
LOOCV 2.129 0.836 0.726 0.725 0.122 0.837 0.834 0.099 0.207 0.209 0.077
2, 2 100% 1.966 0.689 0.832 0.879 0.088 0.824 0.865 0.085 0.173 0.130 0.048
67% 1.947 0.799 0.830 0.827 0.172 0.817 0.818 0.155 0.178 0.179 0.099
50% 1.919 0.877 0.830 0.832 0.156 0.810 0.818 0.148 0.182 0.177 0.086
Fivefold CV 1.966 0.689 0.832 0.833 0.097 0.824 0.823 0.085 0.173 0.173 0.065
LOOCV 1.966 0.689 0.832 0.834 0.100 0.824 0.831 0.088 0.173 0.168 0.069
3, 2 100% 1.833 0.901 0.838 0.891 0.091 0.721 0.760 0.107 0.232 0.188 0.055
67% 1.798 1.064 0.835 0.840 0.183 0.714 0.719 0.176 0.238 0.234 0.106
50% 1.785 1.102 0.834 0.835 0.172 0.712 0.715 0.163 0.239 0.237 0.093
Fivefold CV 1.833 0.901 0.838 0.844 0.094 0.721 0.712 0.101 0.232 0.234 0.071
LOOCV 1.833 0.901 0.838 0.836 0.105 0.721 0.716 0.109 0.232 0.235 0.081
4, 1 100% 2.179 0.585 0.943 0.973 0.040 0.705 0.737 0.085 0.200 0.167 0.051
67% 2.108 0.720 0.940 0.943 0.114 0.698 0.703 0.152 0.205 0.200 0.096
50% 2.050 0.867 0.934 0.934 0.113 0.692 0.697 0.139 0.211 0.209 0.087
Fivefold CV 2.179 0.585 0.943 0.942 0.057 0.705 0.705 0.087 0.200 0.199 0.059
LOOCV 2.179 0.585 0.943 0.941 0.059 0.705 0.708 0.088 0.200 0.197 0.063
6 1, 4 100% 1.884 0.502 0.846 0.870 0.076 0.955 0.979 0.032 0.089 0.065 0.034
67% 1.783 0.542 0.852 0.858 0.141 0.942 0.942 0.096 0.094 0.092 0.076
50% 1.737 0.574 0.854 0.857 0.119 0.935 0.936 0.088 0.097 0.095 0.063
Fivefold CV 1.884 0.502 0.846 0.853 0.080 0.955 0.950 0.042 0.089 0.089 0.045
LOOCV 1.884 0.502 0.846 0.850 0.080 0.955 0.954 0.040 0.089 0.087 0.046
2, 3 100% 2.726 0.777 0.855 0.889 0.074 0.898 0.928 0.059 0.119 0.088 0.037
67% 2.671 0.877 0.857 0.853 0.150 0.889 0.888 0.122 0.124 0.128 0.083
50% 2.551 0.981 0.863 0.861 0.133 0.874 0.870 0.130 0.131 0.134 0.078
Fivefold CV 2.726 0.777 0.855 0.853 0.080 0.898 0.890 0.063 0.119 0.124 0.053
LOOCV 2.726 0.777 0.855 0.851 0.082 0.898 0.894 0.066 0.119 0.123 0.057
2, 2 100% 2.928 0.687 0.927 0.956 0.049 0.917 0.947 0.047 0.079 0.050 0.030
67% 2.824 0.767 0.931 0.940 0.105 0.906 0.911 0.112 0.084 0.079 0.071
50% 2.759 0.851 0.932 0.932 0.100 0.898 0.896 0.110 0.088 0.090 0.066
Fivefold CV 2.928 0.687 0.927 0.929 0.059 0.917 0.912 0.053 0.079 0.080 0.044
LOOCV 2.928 0.687 0.927 0.928 0.061 0.917 0.918 0.052 0.079 0.078 0.045
3, 2 100% 3.175 0.831 0.904 0.942 0.064 0.846 0.876 0.071 0.131 0.098 0.042
67% 3.126 0.952 0.903 0.898 0.142 0.840 0.833 0.139 0.135 0.139 0.087
50% 3.088 1.059 0.901 0.901 0.128 0.834 0.828 0.125 0.139 0.143 0.075
Fivefold CV 3.175 0.831 0.904 0.903 0.074 0.846 0.839 0.073 0.131 0.135 0.057
LOOCV 3.175 0.831 0.904 0.902 0.077 0.846 0.842 0.077 0.131 0.134 0.061
4, 1 100% 3.930 0.643 0.962 0.985 0.030 0.834 0.858 0.067 0.115 0.091 0.041
67% 3.831 0.827 0.957 0.954 0.109 0.826 0.822 0.133 0.121 0.125 0.083
50% 3.716 1.000 0.956 0.956 0.091 0.816 0.818 0.122 0.128 0.127 0.072
Fivefold CV 3.930 0.643 0.962 0.961 0.047 0.834 0.825 0.072 0.115 0.119 0.051
LOOCV 3.930 0.643 0.962 0.962 0.046 0.834 0.830 0.070 0.115 0.117 0.051
Abbreviation: LOOCV, leave-one-out cross-validation.
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Table 3 Simulated means and standard deviations (σ) of the detected cutoff (ĉ), and of estimated sensitivity , specificity and
misclassification rate ( ) with n¼ 100 and p¼0.6. Se, Sp and indicate the true performances
Δμ σ1, σ2 δ ĉ σĉ Se Sp
4 1, 4 100% 1.754 0.432 0.712 0.725 0.067 0.947 0.967 0.035 0.194 0.178 0.039
67% 1.721 0.480 0.714 0.707 0.116 0.940 0.938 0.085 0.196 0.200 0.073
50% 1.669 0.496 0.719 0.718 0.094 0.933 0.931 0.084 0.196 0.197 0.056
Fivefold CV 1.754 0.432 0.712 0.714 0.064 0.947 0.940 0.042 0.194 0.195 0.044
LOOCV 1.754 0.432 0.712 0.712 0.068 0.947 0.944 0.043 0.194 0.195 0.047
2, 3 100% 2.107 0.700 0.731 0.755 0.084 0.840 0.874 0.075 0.226 0.198 0.039
67% 2.102 0.784 0.730 0.730 0.128 0.836 0.834 0.136 0.228 0.228 0.072
50% 2.082 0.878 0.730 0.732 0.123 0.830 0.830 0.134 0.230 0.230 0.064
Fivefold CV 2.107 0.700 0.731 0.734 0.076 0.840 0.836 0.072 0.226 0.225 0.048
LOOCV 2.107 0.700 0.731 0.732 0.087 0.840 0.840 0.080 0.226 0.225 0.057
2, 2 100% 1.967 0.575 0.836 0.856 0.073 0.828 0.861 0.073 0.168 0.142 0.037
67% 1.972 0.641 0.833 0.832 0.115 0.826 0.825 0.135 0.170 0.170 0.069
50% 1.980 0.691 0.830 0.829 0.107 0.825 0.829 0.123 0.172 0.171 0.059
Fivefold CV 1.967 0.575 0.836 0.835 0.066 0.828 0.826 0.072 0.168 0.169 0.046
LOOCV 1.967 0.575 0.836 0.836 0.077 0.828 0.829 0.077 0.168 0.167 0.054
3, 2 100% 1.769 0.688 0.854 0.876 0.076 0.717 0.750 0.091 0.201 0.174 0.039
67% 1.780 0.789 0.849 0.848 0.120 0.717 0.712 0.154 0.204 0.206 0.077
50% 1.692 0.877 0.855 0.858 0.108 0.706 0.703 0.144 0.205 0.204 0.059
Fivefold CV 1.769 0.688 0.854 0.853 0.071 0.717 0.715 0.088 0.201 0.202 0.050
LOOCV 1.769 0.688 0.854 0.853 0.082 0.717 0.716 0.095 0.201 0.202 0.058
4, 1 100% 2.202 0.434 0.951 0.964 0.036 0.708 0.730 0.073 0.146 0.130 0.032
67% 2.185 0.528 0.947 0.949 0.070 0.706 0.706 0.132 0.149 0.149 0.063
50% 2.115 0.665 0.945 0.945 0.074 0.699 0.698 0.117 0.153 0.155 0.054
Fivefold CV 2.202 0.434 0.951 0.950 0.039 0.708 0.705 0.075 0.146 0.149 0.039
LOOCV 2.202 0.434 0.951 0.952 0.041 0.708 0.707 0.076 0.146 0.146 0.041
6 1, 4 100% 1.921 0.423 0.845 0.852 0.051 0.962 0.980 0.026 0.108 0.097 0.031
67% 1.859 0.470 0.848 0.847 0.086 0.954 0.954 0.073 0.109 0.111 0.057
50% 1.840 0.514 0.849 0.848 0.074 0.950 0.952 0.069 0.111 0.111 0.048
Fivefold CV 1.921 0.423 0.845 0.844 0.050 0.962 0.959 0.033 0.108 0.110 0.035
LOOCV 1.921 0.423 0.845 0.843 0.052 0.962 0.962 0.034 0.108 0.110 0.037
2, 3 100% 2.730 0.650 0.857 0.874 0.057 0.903 0.930 0.049 0.125 0.103 0.031
67% 2.675 0.780 0.858 0.856 0.100 0.894 0.896 0.109 0.128 0.127 0.061
50% 2.646 0.824 0.860 0.864 0.085 0.889 0.893 0.098 0.129 0.125 0.050
Fivefold CV 2.730 0.650 0.857 0.859 0.054 0.903 0.899 0.052 0.125 0.125 0.040
LOOCV 2.730 0.650 0.857 0.858 0.060 0.903 0.903 0.054 0.125 0.124 0.044
2, 2 100% 2.939 0.537 0.930 0.943 0.038 0.922 0.946 0.042 0.073 0.056 0.024
67% 2.887 0.622 0.931 0.931 0.072 0.916 0.916 0.091 0.075 0.075 0.049
50% 2.830 0.709 0.933 0.933 0.068 0.909 0.908 0.088 0.077 0.077 0.043
Fivefold CV 2.939 0.537 0.930 0.930 0.040 0.922 0.922 0.045 0.073 0.073 0.032
LOOCV 2.939 0.537 0.930 0.930 0.042 0.922 0.922 0.047 0.073 0.073 0.035
3, 2 100% 3.168 0.645 0.911 0.929 0.048 0.849 0.876 0.059 0.114 0.092 0.029
67% 3.136 0.736 0.910 0.913 0.086 0.845 0.844 0.115 0.116 0.114 0.057
50% 3.115 0.856 0.908 0.909 0.084 0.841 0.839 0.106 0.119 0.119 0.051
Fivefold CV 3.168 0.645 0.911 0.911 0.048 0.849 0.848 0.060 0.114 0.114 0.038
LOOCV 3.168 0.645 0.911 0.912 0.052 0.849 0.849 0.064 0.114 0.113 0.041
4, 1 100% 3.949 0.500 0.968 0.978 0.025 0.836 0.856 0.059 0.085 0.071 0.026
67% 3.861 0.634 0.968 0.969 0.051 0.830 0.828 0.112 0.087 0.088 0.050
50% 3.801 0.748 0.966 0.968 0.053 0.825 0.821 0.100 0.090 0.091 0.045
Fivefold CV 3.949 0.500 0.968 0.968 0.028 0.836 0.832 0.062 0.085 0.087 0.032
LOOCV 3.949 0.500 0.968 0.969 0.029 0.836 0.835 0.061 0.085 0.085 0.032
Abbreviation: LOOCV, leave-one-out cross-validation.
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Table 4 Simulated means and standard deviations (σ) of the detected cutoff (ĉ), and of estimated sensitivity , specificity , and
misclassification rate ( ) with n¼ 100 and p¼0.4. Se, Sp, and indicate the true performances
Δμ σ1, σ2 δ ĉ σĉ Se Sp
4 1, 4 100% 1.759 0.421 0.711 0.728 0.075 0.948 0.962 0.037 0.147 0.131 0.032
67% 1.721 0.466 0.714 0.712 0.134 0.941 0.940 0.071 0.150 0.151 0.064
50% 1.678 0.502 0.718 0.713 0.110 0.934 0.934 0.074 0.152 0.154 0.056
Fivefold CV 1.759 0.421 0.711 0.709 0.075 0.948 0.944 0.037 0.147 0.149 0.039
LOOCV 1.759 0.421 0.711 0.709 0.076 0.948 0.947 0.040 0.147 0.147 0.041
2, 3 100% 2.153 0.674 0.726 0.752 0.089 0.846 0.868 0.076 0.202 0.178 0.039
67% 2.174 0.778 0.722 0.712 0.151 0.844 0.842 0.120 0.204 0.210 0.074
50% 2.138 0.811 0.725 0.717 0.132 0.839 0.838 0.116 0.206 0.210 0.065
Fivefold CV 2.153 0.674 0.726 0.720 0.085 0.846 0.844 0.071 0.202 0.206 0.049
LOOCV 2.153 0.674 0.726 0.720 0.093 0.846 0.846 0.081 0.202 0.204 0.057
2, 2 100% 2.034 0.550 0.828 0.859 0.072 0.837 0.856 0.069 0.167 0.143 0.036
67% 2.006 0.644 0.829 0.827 0.129 0.830 0.829 0.114 0.170 0.171 0.068
50% 2.008 0.695 0.827 0.827 0.124 0.829 0.829 0.107 0.172 0.172 0.057
Fivefold CV 2.034 0.550 0.828 0.828 0.070 0.837 0.830 0.066 0.167 0.170 0.046
LOOCV 2.034 0.550 0.828 0.829 0.077 0.837 0.836 0.074 0.167 0.167 0.051
3, 2 100% 1.862 0.699 0.843 0.876 0.076 0.727 0.752 0.085 0.226 0.198 0.042
67% 1.875 0.760 0.840 0.841 0.134 0.728 0.730 0.128 0.228 0.226 0.073
50% 1.878 0.870 0.835 0.833 0.132 0.726 0.726 0.121 0.230 0.231 0.062
Fivefold CV 1.862 0.699 0.843 0.843 0.072 0.727 0.729 0.077 0.226 0.225 0.049
LOOCV 1.862 0.699 0.843 0.844 0.080 0.727 0.732 0.085 0.226 0.223 0.055
4, 1 100% 2.235 0.427 0.948 0.966 0.035 0.711 0.725 0.064 0.194 0.178 0.038
67% 2.225 0.504 0.944 0.938 0.089 0.709 0.702 0.112 0.197 0.202 0.071
50% 2.194 0.586 0.942 0.939 0.082 0.706 0.705 0.096 0.199 0.201 0.057
Fivefold CV 2.235 0.427 0.948 0.945 0.040 0.711 0.707 0.064 0.194 0.197 0.043
LOOCV 2.235 0.427 0.948 0.945 0.043 0.711 0.708 0.067 0.194 0.197 0.045
6 1, 4 100% 1.950 0.409 0.843 0.856 0.058 0.965 0.978 0.025 0.084 0.071 0.026
67% 1.908 0.454 0.845 0.841 0.112 0.960 0.960 0.056 0.086 0.087 0.050
50% 1.882 0.485 0.847 0.846 0.091 0.955 0.957 0.060 0.088 0.088 0.045
Fivefold CV 1.950 0.409 0.843 0.843 0.059 0.965 0.961 0.029 0.084 0.086 0.032
LOOCV 1.950 0.409 0.843 0.843 0.061 0.965 0.964 0.031 0.084 0.084 0.034
2, 3 100% 2.792 0.623 0.852 0.877 0.056 0.909 0.926 0.047 0.114 0.093 0.029
67% 2.790 0.710 0.851 0.848 0.111 0.906 0.907 0.088 0.116 0.116 0.060
50% 2.741 0.781 0.853 0.855 0.096 0.899 0.899 0.085 0.119 0.119 0.050
Fivefold CV 2.792 0.623 0.852 0.853 0.058 0.909 0.906 0.048 0.114 0.115 0.038
LOOCV 2.792 0.623 0.852 0.852 0.062 0.909 0.908 0.053 0.114 0.114 0.043
2, 2 100% 2.988 0.543 0.927 0.947 0.039 0.925 0.941 0.038 0.074 0.057 0.023
67% 2.955 0.631 0.927 0.924 0.089 0.921 0.919 0.077 0.077 0.079 0.049
50% 2.904 0.678 0.929 0.930 0.071 0.916 0.916 0.068 0.079 0.078 0.041
Fivefold CV 2.988 0.543 0.927 0.926 0.043 0.925 0.923 0.038 0.074 0.075 0.031
LOOCV 2.988 0.543 0.927 0.926 0.044 0.925 0.925 0.040 0.074 0.074 0.033
3, 2 100% 3.210 0.634 0.908 0.933 0.047 0.852 0.871 0.055 0.125 0.104 0.031
67% 3.182 0.716 0.908 0.911 0.098 0.849 0.849 0.098 0.128 0.125 0.061
50% 3.133 0.820 0.908 0.910 0.090 0.843 0.843 0.091 0.131 0.129 0.051
Fivefold CV 3.210 0.634 0.908 0.906 0.051 0.852 0.851 0.053 0.125 0.127 0.039
LOOCV 3.210 0.634 0.908 0.908 0.054 0.852 0.853 0.058 0.125 0.124 0.043
4, 1 100% 3.989 0.451 0.967 0.982 0.023 0.839 0.855 0.048 0.110 0.094 0.029
67% 3.944 0.564 0.965 0.967 0.062 0.836 0.838 0.091 0.113 0.111 0.056
50% 3.903 0.630 0.964 0.965 0.059 0.832 0.838 0.081 0.115 0.111 0.048
Fivefold CV 3.989 0.451 0.967 0.964 0.032 0.839 0.842 0.049 0.110 0.109 0.034
LOOCV 3.989 0.451 0.967 0.965 0.033 0.839 0.843 0.051 0.110 0.108 0.036
Abbreviation: LOOCV, leave-one-out cross-validation.
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Table 5 Simulated means and standard deviations (σ) of the detected cutoff (ĉ), and of estimated sensitivity , specificity , and
misclassification rate ( ) with n¼ 200 and p¼0.6. Se, Sp, and indicate the true performances
Δμ σ1, σ2 δ ĉ σĉ Se Sp
4 1, 4 100% 1.740 0.342 0.713 0.723 0.050 0.950 0.963 0.028 0.192 0.181 0.029
67% 1.721 0.384 0.715 0.715 0.081 0.946 0.946 0.057 0.193 0.193 0.051
50% 1.710 0.427 0.715 0.716 0.071 0.942 0.942 0.058 0.194 0.193 0.042
Fivefold CV 1.740 0.342 0.713 0.716 0.048 0.950 0.949 0.029 0.192 0.191 0.032
LOOCV 1.740 0.342 0.713 0.716 0.051 0.950 0.950 0.032 0.192 0.190 0.034
2, 3 100% 2.212 0.559 0.721 0.736 0.069 0.857 0.877 0.060 0.225 0.208 0.030
67% 2.175 0.645 0.724 0.724 0.099 0.850 0.853 0.102 0.226 0.225 0.053
50% 2.167 0.676 0.724 0.726 0.095 0.848 0.846 0.096 0.226 0.226 0.045
Fivefold CV 2.212 0.559 0.721 0.727 0.060 0.857 0.851 0.057 0.225 0.224 0.035
LOOCV 2.212 0.559 0.721 0.723 0.070 0.857 0.855 0.064 0.225 0.224 0.042
2, 2 100% 1.960 0.436 0.840 0.851 0.053 0.831 0.852 0.057 0.163 0.149 0.025
67% 1.958 0.501 0.839 0.836 0.083 0.829 0.829 0.095 0.165 0.167 0.048
50% 1.952 0.567 0.838 0.836 0.082 0.826 0.829 0.093 0.167 0.167 0.041
Fivefold CV 1.960 0.436 0.840 0.838 0.048 0.831 0.833 0.054 0.163 0.164 0.031
LOOCV 1.960 0.436 0.840 0.838 0.054 0.831 0.834 0.060 0.163 0.163 0.035
3, 2 100% 1.824 0.555 0.853 0.867 0.063 0.725 0.746 0.072 0.198 0.181 0.028
67% 1.807 0.627 0.852 0.857 0.088 0.722 0.725 0.117 0.200 0.195 0.052
50% 1.826 0.676 0.849 0.850 0.087 0.724 0.725 0.103 0.201 0.200 0.043
Fivefold CV 1.824 0.555 0.853 0.853 0.058 0.725 0.726 0.067 0.198 0.198 0.034
LOOCV 1.824 0.555 0.853 0.855 0.066 0.725 0.726 0.073 0.198 0.197 0.040
4, 1 100% 2.217 0.350 0.954 0.963 0.028 0.710 0.723 0.053 0.144 0.133 0.024
67% 2.195 0.410 0.953 0.955 0.047 0.707 0.712 0.094 0.145 0.142 0.045
50% 2.186 0.462 0.951 0.952 0.050 0.706 0.706 0.083 0.147 0.146 0.037
Fivefold CV 2.217 0.350 0.954 0.955 0.027 0.710 0.709 0.053 0.144 0.143 0.027
LOOCV 2.217 0.350 0.954 0.954 0.032 0.710 0.712 0.055 0.144 0.142 0.030
6 1, 4 100% 1.964 0.358 0.843 0.848 0.036 0.968 0.978 0.021 0.107 0.100 0.021
67% 1.947 0.389 0.843 0.839 0.063 0.965 0.966 0.047 0.108 0.110 0.039
50% 1.939 0.438 0.844 0.843 0.054 0.963 0.964 0.042 0.109 0.109 0.032
Fivefold CV 1.964 0.358 0.843 0.842 0.036 0.968 0.966 0.023 0.107 0.108 0.025
LOOCV 1.964 0.358 0.843 0.842 0.038 0.968 0.967 0.024 0.107 0.108 0.026
2, 3 100% 2.783 0.506 0.855 0.865 0.044 0.911 0.926 0.039 0.123 0.111 0.022
67% 2.757 0.588 0.856 0.853 0.070 0.907 0.906 0.076 0.124 0.126 0.043
50% 2.751 0.633 0.855 0.855 0.064 0.905 0.905 0.068 0.125 0.125 0.034
Fivefold CV 2.783 0.506 0.855 0.855 0.041 0.911 0.910 0.039 0.123 0.123 0.026
LOOCV 2.783 0.506 0.855 0.855 0.045 0.911 0.912 0.042 0.123 0.122 0.029
2, 2 100% 2.971 0.450 0.930 0.939 0.031 0.926 0.940 0.032 0.071 0.061 0.018
67% 2.949 0.497 0.931 0.931 0.052 0.924 0.925 0.061 0.072 0.072 0.033
50% 2.958 0.541 0.929 0.930 0.049 0.923 0.925 0.057 0.073 0.072 0.028
Fivefold CV 2.971 0.450 0.930 0.929 0.030 0.926 0.926 0.032 0.071 0.072 0.022
LOOCV 2.971 0.450 0.930 0.930 0.033 0.926 0.927 0.035 0.071 0.071 0.025
3, 2 100% 3.202 0.515 0.912 0.923 0.039 0.854 0.870 0.046 0.111 0.098 0.022
67% 3.182 0.594 0.912 0.914 0.062 0.851 0.853 0.085 0.113 0.110 0.040
50% 3.192 0.638 0.910 0.911 0.060 0.851 0.853 0.072 0.114 0.112 0.035
Fivefold CV 3.202 0.515 0.912 0.913 0.036 0.854 0.853 0.046 0.111 0.111 0.027
LOOCV 3.202 0.515 0.912 0.914 0.041 0.854 0.854 0.049 0.111 0.110 0.031
4, 1 100% 3.999 0.362 0.970 0.977 0.020 0.840 0.852 0.043 0.082 0.073 0.019
67% 3.988 0.425 0.969 0.969 0.040 0.839 0.839 0.079 0.083 0.084 0.037
50% 3.977 0.455 0.968 0.967 0.038 0.838 0.839 0.064 0.084 0.084 0.030
Fivefold CV 3.999 0.362 0.970 0.970 0.020 0.840 0.840 0.043 0.082 0.082 0.022
LOOCV 3.999 0.362 0.970 0.971 0.022 0.840 0.841 0.044 0.082 0.081 0.023
Abbreviation: LOOCV, leave-one-out cross-validation.
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Table 6 Simulated means and standard deviations (σ) of the detected cutoff (ĉ), and of estimated sensitivity , specificity and
misclassification rate ( ) with n¼ 200 and p¼0.4. Se, Sp, and indicate the true performances
Δμ σ1, σ2 δ ĉ σĉ Se Sp
4 1, 4 100% 1.783 0.353 0.710 0.721 0.055 0.954 0.962 0.030 0.144 0.134 0.024
67% 1.774 0.386 0.710 0.710 0.094 0.951 0.952 0.049 0.145 0.146 0.044
50% 1.763 0.424 0.711 0.709 0.079 0.948 0.946 0.052 0.147 0.149 0.039
Fivefold CV 1.783 0.353 0.710 0.709 0.053 0.954 0.953 0.028 0.144 0.144 0.027
LOOCV 1.783 0.353 0.710 0.708 0.056 0.954 0.955 0.031 0.144 0.144 0.030
2, 3 100% 2.147 0.562 0.728 0.748 0.071 0.849 0.863 0.062 0.199 0.183 0.028
67% 2.145 0.633 0.727 0.726 0.110 0.847 0.846 0.092 0.201 0.203 0.052
50% 2.151 0.689 0.726 0.724 0.104 0.845 0.846 0.092 0.202 0.203 0.046
Fivefold CV 2.147 0.562 0.728 0.726 0.066 0.849 0.849 0.055 0.199 0.200 0.034
LOOCV 2.147 0.562 0.728 0.726 0.073 0.849 0.848 0.063 0.199 0.201 0.040
2, 2 100% 2.014 0.463 0.833 0.851 0.059 0.837 0.851 0.057 0.165 0.149 0.026
67% 2.043 0.504 0.829 0.828 0.097 0.839 0.838 0.085 0.165 0.166 0.048
50% 2.017 0.578 0.830 0.830 0.095 0.834 0.834 0.085 0.168 0.167 0.041
Fivefold CV 2.014 0.463 0.833 0.831 0.054 0.837 0.837 0.050 0.165 0.165 0.031
LOOCV 2.014 0.463 0.833 0.831 0.061 0.837 0.840 0.058 0.165 0.163 0.037
3, 2 100% 1.838 0.545 0.852 0.873 0.059 0.727 0.740 0.066 0.223 0.207 0.030
67% 1.860 0.599 0.847 0.848 0.097 0.728 0.728 0.095 0.224 0.225 0.053
50% 1.837 0.663 0.848 0.848 0.094 0.725 0.726 0.091 0.226 0.225 0.045
Fivefold CV 1.838 0.545 0.852 0.849 0.055 0.727 0.727 0.060 0.223 0.224 0.035
LOOCV 1.838 0.545 0.852 0.851 0.062 0.727 0.726 0.068 0.223 0.224 0.042
4, 1 100% 2.242 0.336 0.952 0.964 0.029 0.712 0.722 0.048 0.192 0.181 0.027
67% 2.229 0.397 0.950 0.950 0.060 0.710 0.712 0.079 0.194 0.193 0.047
50% 2.225 0.424 0.949 0.949 0.051 0.710 0.715 0.068 0.194 0.192 0.040
Fivefold CV 2.242 0.336 0.952 0.951 0.030 0.712 0.713 0.046 0.192 0.192 0.030
LOOCV 2.242 0.336 0.952 0.952 0.032 0.712 0.713 0.048 0.192 0.191 0.031
6 1, 4 100% 1.977 0.345 0.842 0.849 0.043 0.969 0.975 0.021 0.082 0.075 0.019
67% 1.975 0.394 0.842 0.837 0.074 0.967 0.966 0.039 0.083 0.086 0.034
50% 1.943 0.419 0.843 0.843 0.065 0.964 0.963 0.040 0.084 0.085 0.030
Fivefold CV 1.977 0.345 0.842 0.840 0.043 0.969 0.967 0.022 0.082 0.084 0.022
LOOCV 1.977 0.345 0.842 0.840 0.044 0.969 0.969 0.024 0.082 0.083 0.023
2, 3 100% 2.809 0.511 0.853 0.869 0.047 0.913 0.923 0.038 0.111 0.099 0.021
67% 2.820 0.591 0.851 0.853 0.084 0.912 0.913 0.064 0.113 0.112 0.042
50% 2.763 0.651 0.854 0.857 0.076 0.905 0.905 0.066 0.115 0.114 0.037
Fivefold CV 2.809 0.511 0.853 0.853 0.045 0.913 0.913 0.035 0.111 0.111 0.026
LOOCV 2.809 0.511 0.853 0.853 0.049 0.913 0.913 0.041 0.111 0.111 0.031
2, 2 100% 3.013 0.419 0.928 0.940 0.031 0.930 0.938 0.030 0.071 0.061 0.017
67% 3.008 0.475 0.927 0.926 0.063 0.928 0.927 0.054 0.072 0.074 0.035
50% 2.967 0.542 0.928 0.929 0.055 0.924 0.923 0.054 0.074 0.075 0.029
Fivefold CV 3.013 0.419 0.928 0.926 0.033 0.930 0.929 0.029 0.071 0.072 0.022
LOOCV 3.013 0.419 0.928 0.927 0.034 0.930 0.930 0.032 0.071 0.071 0.024
3, 2 100% 3.245 0.506 0.909 0.924 0.040 0.857 0.865 0.044 0.122 0.112 0.023
67% 3.235 0.585 0.908 0.909 0.073 0.855 0.852 0.071 0.124 0.125 0.042
50% 3.244 0.658 0.905 0.905 0.072 0.855 0.854 0.067 0.125 0.126 0.036
Fivefold CV 3.245 0.506 0.909 0.908 0.039 0.857 0.853 0.042 0.122 0.125 0.028
LOOCV 3.245 0.506 0.909 0.908 0.044 0.857 0.854 0.046 0.122 0.124 0.032
4, 1 100% 4.043 0.360 0.967 0.978 0.020 0.843 0.849 0.036 0.107 0.099 0.021
67% 4.035 0.427 0.965 0.966 0.047 0.842 0.842 0.063 0.109 0.109 0.039
50% 4.019 0.468 0.965 0.965 0.042 0.841 0.839 0.056 0.110 0.111 0.032
Fivefold CV 4.043 0.360 0.967 0.967 0.022 0.843 0.842 0.036 0.107 0.108 0.024
LOOCV 4.043 0.360 0.967 0.968 0.024 0.843 0.843 0.037 0.107 0.107 0.025
Abbreviation: LOOCV, leave-one-out cross-validation.
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the variance of ĉ increases as the training percentage
decreases; as a consequence, the true performance indica-
tors appear to get a little worse as δ decreases, since there is
greater probability that the estimated cutoff assumes values
far from the aforementioned intersection point. As expected,
the true performances improve as the sample size and the
distance between the distributions of diseased and non-
diseased individuals (δμ) increase. Similarly, the true sensi-
tivity increases as the variability of the classifier decreases
among diseased individuals (σ2), just as the true specificity
increases as σ1 decreases.
Quite evidently, assessing the test performance on the
training set (δ¼100%) leads to an overestimation of the true
sensitivity and specificity, and consequently an underesti-
mation of the true misclassification rate in all scenarios. In
particular, the bias is higher when estimating sensitivity
with a low prevalence (on average less fewer diseased
individuals are sampled) and when estimating specificity
with a high prevalence (on average less fewer nondiseased
individuals are sampled). The bias is substantially not affect-
ed by increasing δμ or changing σ1 and σ2, while it decreases
as the sample size increases.
When a single split or CV is performed, , , and are
unbiased estimators of the true performance indicators in all
scenarios. However, in the case of a single split, , , and
are affected by higher variability, especially with smaller
sample sizes, higher population variances of the classifier,
and a higher training proportion (δ¼67%). Conversely, CV
performs the best in all scenarios.
For each scenario, ►Figs. 2, 3, and 4 represent the true
misclassificationrates foreachcandidatecutoffscj (blackcurve)
and the empirical (simulated)means of the error rates estimat-
ed as thedifferent cj are selected as the optimal cutoff using the
different training percentages (δ¼100%, 67%, 50%) and CV. For
all scenarios, the lines in green (δ¼67%), blue (δ¼50%), light
blue (fivefold CV), andmagenta (LOOCV) lie on the black curve
[the true ], meaning that, once a given ĉδ is obtained, the
true classification error is correctly estimated. By contrast,
the red line (δ¼100%) lies below the black line, indicating an
underestimation of the true classification error. Since the red
and the black curves appear to be parallel, the bias is
approximately the same regardless of the optimal cutoff
estimated. ►Figures 3 and 4 show that the bias reduces as
the sample size n increases from50 to 100 or 200 individuals.
It is worth noting that the means of the simulated error
estimatesgetmorewiggly for themost external cutoffs; this is
due to the low probability of detecting such cutoffs as optimal
over the 1,000 replicates. Due to the lower variance of ĉ100%
highlighted in►Tables 1–5 to 6, the lines in red, light blue, and
magenta are shorter than the others. Since the most external
cutoffs are associated with higher true misclassification rates,
this would explain the somewhat better true overall perform-
ances highlighted in ►Tables 1–5 to 6 when δ¼100%.
Validation of the Italian CARATkids Questionnaire
Due to themoderate sample size (n¼112), the lowestimated
prevalence (17.86%, i.e., C-ACT total score 19 in 20/112
children) and the sample estimates Δμì , σ and
σ , δ¼50% were used as it should provide lower uncer-
tainty of γ with a negligible loss of true performance
(►Table 3); CVwas also performed. Due to the random group
assignment, no significant differences were found between
the training set and the test set (►Table 7).
At T0 and T1 CARATkids score (increasing for decreasing
disease control) showed significant intra-visit correlation
(Spearman’s rho in the training set) with C-ACT (increasing
for increasingdisease control): ρ¼0.65 (p-value<0.001) at
T0 and ρ¼0.61 (p-value<0.001) at T1. The inter-visit
correlation was weaker but statistically significant: ρ¼
0.52 (p-value<0.001).
►Figure 5 depicts the ROC curve evaluated on the training
set. The overall CARATkids score showed a good ability to
predict a C-ACTscore19: the AUCwas 0.91 (95% confidence
interval [CI]: 0.82–0.99), and the optimal threshold was
ĉ50%¼5.5, associatedwith a 91% sensitivity, a 76% specificity,
and a 21%misclassification rate on the same training sample.
The rule obtained (CARATkids >5.5 for identifying uncon-
trolled asthma)was therefore tested on the test set. It yielded
an estimated sensitivity of 78% and an estimated specificity
of 77%. The estimated misclassification rate was 0.23, with
95% CI: 0.11 to 0.34 (usual CI for a proportion), indicating an
acceptable discriminant validity. The optimal threshold was
the same when estimated on the whole sample (ĉ100%¼5.5).
In this case, fivefold CV yielded an estimated sensitivity of
75%, an estimated specificity of 78%, and a misclassification
rate of 0.22, with 95% CI: 0.14 to 0.30. LOOCV yielded an
estimated sensitivity of 75%, an estimated specificity of 76%,
and a misclassification rate of 0.24, with 95% CI: 0.16 to 0.32.
Discussion
In this article, two common approaches for estimating and
validating simple classification rules have been described in
the context of ROC analysis: the focus has been on the
inferential implications of splitting (once or repeatedly) or
not the dataset into training and test sets. In fact, though
well addressed in other areas, this topic still appears to be
overlooked among medical researchers dealing with clinical
data.
A simulation study showed that splitting the sample into
training and test sets allows unbiased estimation of sensitiv-
ity, specificity, and misclassification rate. A single split of the
sample produces more fluctuating estimates (higher vari-
ance) for both the cutoff and the performance indicators. The
problem of higher variance is of some importance, and has
raised questions about the ideal splitting proportion, espe-
cially when the sample size n is small (<100). Moreover, this
approach slightly reduces the true performance of the clas-
sification method. This aspect should not discourage the use
of a test set, even when the total sample size is n50, but
rather, it may suggest reducing the training proportion.
Indeed, while using a smaller training set does not appear
to affect true performances considerably (►Tables 1 and 2), it
may help to reduce the variance of their estimates by
increasing the number of individuals in the test set. In
general, very small sample sizes (n<50) together with
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very small (or very high) expected prevalences (p<0.20)
would discourage the use of ROC analysis in simple random
samples (due to the small proportion of diseased individuals
in the sample). In such situations, it would be preferable to
use CV, or alternatively, stratified sampling (to fix the
number of diseased and nondiseased individuals), or more
advanced methods like SMOTE.31,32 The issue of the higher
variance after a single sample split can be quantified by
deriving standard CIs for proportions; conversely, the bias of
6, 7, and 8 does not allow computation of valid CIs.
For the sake of brevity, the simulation studywas limited to
normal distribution only, and moreover the properties of a
Fig. 2 Misclassification rates given the optimal cutoff, for n¼ 50 (►Tables 1 and 2). Black line: true error. Red line: mean error estimated using
the whole sample. Green line: mean error estimated with 67% training and 33% test. Blue line: mean error estimated with 50% training and 50%
test. Light blue line: mean error estimated with fivefold cross-validation. Magenta line: mean error estimated with leave one out cross-validation.
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single utility function (Youden’s index) were assessed. De-
spite representing a possible limitation of the present study,
it might be speculated that the main findings should not be
much influenced by the choice of simulation setting. Indeed,
the main goal of the article was simply to show, empirically,
the usefulness of using independent test samples, a topic that
has been well studied in other contexts, but overlooked in
medical literature about ROC analysis.
The motivating dataset of 112 Italian outpatient children
represented a case in point. By now the CARATkids ques-
tionnaire for assessing disease control in children with
asthma and rhinitis has been validated in three different
Fig. 3 Misclassification rates given the optimal cutoff, for n¼ 100 (►Tables 3 and 4). Black line: true error. Red line: mean error estimated using
the whole sample. Green line: mean error estimated with 67% training and 33% test. Blue line: mean error estimated with 50% training and 50%
test. Light blue line: mean error estimated with fivefold cross-validation. Magenta line: mean error estimated with leave one out cross-validation.
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languages.27–29 However, none of these studies performed a
ROC analysis with a sample split.
The intravisit (cross-sectional validity) and intervisit
(longitudinal validity) correlations with C-ACT were similar
to those found in all the previous aforementioned stud-
ies.27–29 Concerning prediction of asthma control (discrimi-
nant validity), it is worth noting that the ROC analysis using a
50% sample split showed high sensitivity in the training set
as in the previous studies,27,28while it was ofmoremoderate
intensity in the independent test set. This might suggest that
the CARATkids misclassification rate may have been under-
estimated in previous assessments. Overall, the results
Fig. 4 Misclassification rates given the optimal cutoff, for n¼ 200 (►Tables 5 and 6). Black line: true error. Red line: mean error estimated using
the whole sample. Green line: mean error estimated with 67% training and 33% test. Blue line: mean error estimated with 50% training and 50%
test. Light blue line: mean error estimated with fivefold cross-validation. Magenta line: mean error estimated with leave one out cross-validation.
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highlight the clinical validity of the Italian version of the
CARATkids questionnaire for assessment of disease control in
children with asthma and rhinitis.
Conclusions
Medical researchers dealing with clinical data should care-
fully consider the usefulness of splitting, when possible, the
study sample into a training sample (where the optimal test
is derived) and a test sample (where performance or error
rates are estimated) when performing a ROC analysis, or
alternatively using CV. The results of the present study
support the use of CARATkids as a valid questionnaire to
assess disease control in Italian children with asthma and
rhinitis; its use helps to optimize simultaneous evaluation of
allergic rhinitis and asthma, contributing to more compre-
hensive health care in children.
Note
All data and materials are available upon request.
Fig. 5 Receiver operating characteristic curve for the ability of CARATkids to predict a the Childhood Asthma Control Test19. AUC, area under
the curve.
Table 7 Patient characteristics
Training set
n¼56
Test set
n¼ 56
All
n¼ 112
p-Value
Gender, n (%) 0.69
Male 36 (64.29%) 39 (69.64%) 75 (66.96%)
Female 20 (35.71%) 17 (30.36%) 37 (33.04%)
Age, mean (SD) 8.29 (1.69) 8.32 (1.57) 8.3 (1.63) 0.91
Height, mean (SD) 131.84 (11.87) 132.60 (9.45) 132.72 (10.68) 0.91
Asthma severity, n (%) 0.33
Intermittent 13 (23.21%) 8 (14.29%) 21 (18.75%)
Persistent 43 (76.79%) 48 (85.71%) 91 (81.25%)
Rhinitis severity, n (%) 0.93
Intermittent 25 (44.64%) 24 (42.86%) 49 (43.75%)
Persistent 31 (55.36%) 32 (57.14%) 63 (56.25%)
CARATkids, mean (SD) 4.8 (3.35) 4.54 (3.34) 4.67 (3.33) 0.71
C-ACT, mean (SD) 22.96 (3.45) 22.88 (3.58) 22.92 (3.5) 0.89
C-ACT19, n (%) 11 (19.64%) 9 (16.07%) 20 (17.86%)
Abbreviations: C-ACT, the Childhood Asthma Control Test; SD, standard deviation.
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